# Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V

> **NCT01229397** · PHASE3 · COMPLETED · sponsor: **Crucell Holland BV** · enrollment: 205 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Inflexal V
- **BIOLOGICAL:** Inflexal V

## Key facts

- **NCT ID:** NCT01229397
- **Lead sponsor:** Crucell Holland BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2014-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01229397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01229397, "Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01229397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*